Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2023-09-07 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
北京德恒律师事务所关于东北制药集团股份有限公司2023年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedural compliance of a company's 2023 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data but focuses on the legal validation of the meeting process and resolutions. This type of document is typically associated with announcements related to shareholder meetings and voting results rather than the meeting materials themselves or the full annual or interim reports. Given the detailed voting results and the nature of the document as a legal opinion on the meeting's validity and voting outcomes, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it contains substantive content about voting results, not just a brief announcement or a report publication notice, so it is not RPA or RNS. Therefore, the classification is DVA with high confidence.
2023-09-07 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2023-09-07 Chinese
关于召开公司2023年第二次临时股东大会的提示性公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2023 second extraordinary general meeting of shareholders, including meeting date, voting procedures, proposals to be voted on, and proxy voting instructions. It does not contain actual financial statements or results, nor is it a transcript or report of the meeting outcomes. It is a notice informing shareholders about the meeting and how to participate. The document length is 3600 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than solicitation materials or proxy statements, the best fit is Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-09-01 Chinese
独立董事对公司第九届董事会第十九次会议相关议案发表的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on a specific board meeting agenda item related to new related-party transactions for the year 2023. It references compliance with stock exchange listing rules and company bylaws. The content is focused on governance and board-level approval rather than financial results, audit, or shareholder voting outcomes. It is not a full report, earnings release, or regulatory filing but rather a management/board-related opinion document. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial data or voting results, so other categories like Annual Report, Earnings Release, or Declaration of Voting Results are not appropriate.
2023-08-30 Chinese
第九届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 15th meeting of the 9th Supervisory Board of Dongbei Pharmaceutical Group Co., Ltd. It includes details about the meeting date, attendance, voting results, and references to related announcements. The content focuses on board-level decisions and governance matters, specifically related to supervisory board resolutions and related party transactions. It does not contain financial statements, audit opinions, or detailed financial data. It is not a report itself but an announcement of a board meeting resolution. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear governance-related content and meeting resolution context.
2023-08-30 Chinese
第九届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the 9th Board of Directors of Northeast Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and mentions related independent director opinions. There is no financial data, no report attached or referenced as being published, and no mention of annual or quarterly reports. The content focuses on board meeting decisions and governance matters, specifically about related party transactions and voting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2023-08-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.